Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.45 Million EUR | -51.13% |
| 2022 | 7.06 Million EUR | -31.76% |
| 2021 | 10.34 Million EUR | 95.15% |
| 2020 | 5.3 Million EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2024 Q2 | 3.19 Million EUR | 0.0% |
| 2023 FY | 3.45 Million EUR | -51.13% |
| 2023 Q1 | 73.34 Thousand EUR | -98.96% |
| 2023 Q2 | 5.75 Million EUR | 7748.53% |
| 2023 Q4 | 3.45 Million EUR | -24.3% |
| 2023 Q3 | 4.55 Million EUR | -20.81% |
| 2022 Q4 | 7.06 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -213.407% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 92.28% |
| Adocia SA | 4.54 Million EUR | 23.995% |
| Aelis Farma SA | 2.04 Million EUR | -68.487% |
| Biophytis S.A. | 3.11 Million EUR | -10.917% |
| Advicenne S.A. | 15.89 Million EUR | 78.293% |
| genOway Société anonyme | 5.51 Million EUR | 37.481% |
| IntegraGen SA | 642.28 Thousand EUR | -437.245% |
| Medesis Pharma S.A. | 1.2 Million EUR | -187.551% |
| Neovacs S.A. | 650 Thousand EUR | -430.864% |
| NFL Biosciences SA | 39.2 Thousand EUR | -8701.916% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 20.794% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -76.022% |
| Sensorion SA | 1.24 Million EUR | -178.071% |
| Theranexus Société Anonyme | 2.46 Million EUR | -40.228% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 11.477% |
| TheraVet SA | 1 Million EUR | -244.855% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 50.035% |
| argenx SE | 15.35 Million EUR | 77.526% |
| BioSenic S.A. | 15.57 Million EUR | 77.842% |
| Celyad Oncology SA | 902 Thousand EUR | -282.552% |
| DBV Technologies S.A. | 4.52 Million USD | 23.76% |
| Galapagos NV | 4.94 Million EUR | 30.206% |
| Genfit S.A. | 62.25 Million EUR | 94.457% |
| GeNeuro SA | 6.49 Million EUR | 46.851% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -903.086% |
| Innate Pharma S.A. | 30.6 Million EUR | 88.726% |
| Inventiva S.A. | 25.61 Million EUR | 86.529% |
| MaaT Pharma SA | 5.42 Million EUR | 36.394% |
| MedinCell S.A. | 52.8 Million EUR | 93.465% |
| Nanobiotix S.A. | 41.66 Million EUR | 91.717% |
| Onward Medical N.V. | 16.3 Million EUR | 78.838% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 90.282% |
| Oxurion NV | 117 Thousand EUR | -2849.244% |
| Pharming Group N.V. | 123.65 Million EUR | 97.21% |
| Poxel S.A. | 40.14 Million EUR | 91.404% |
| GenSight Biologics S.A. | 1.04 Million EUR | -229.257% |
| Transgene SA | 17 Thousand EUR | -20197.735% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.88% |
| Valneva SE | 132.76 Million EUR | 97.401% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |